Phases, active trials: Phase 1: 40, Phase 2: 20, Phase 3: 25, Other: 10
Boehringer Ingelheim is a privately-held pharmaceutical company with major franchises in respiratory disease, metabolic conditions, and oncology. In respiratory, Ofev (nintedanib) for idiopathic pulmonary fibrosis and other fibrosing ILDs continues expanding into new fibrosing lung conditions, while Spiriva and Spiolto anchor the COPD franchise. In metabolic disease, Jardiance (empagliflozin), co-developed with Eli Lilly, has expanded from type 2 diabetes into heart failure with reduced and preserved ejection fraction, and is advancing into CKD. Their oncology pipeline focuses on novel mechanisms in solid tumors, including KRAS SOS1 inhibitors, KRASG12C inhibitors, and immune cell engagers targeting tumor microenvironment.
- Respiratory (IPF, ILD, COPD)
- Metabolic / cardiovascular (SGLT2, HFpEF)
- Oncology (KRAS, SOS1, tumor microenvironment)
- Immunology / inflammation
- CNS
- Jardiance (empagliflozin): SGLT2, T2D/HF/CKD
- Ofev (nintedanib): FGFR, PDGFR, VEGFR: IPF/ILD
- Gilotrif (afatinib): EGFR/HER2 inhibitor, NSCLC
- BI 1701963: SOS1 inhibitor, KRAS-mutant tumors
- BI 905677: KRASG12C inhibitor
- Spesolimab: IL-36R, generalized pustular psoriasis
A primary completion date pushed out, enrollment cut, or a primary endpoint changed in the last 90 days. Active trials only.
| Trial | Warning signs | Status |
|---|---|---|
| Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With… NCT06581432 | Primary completion moved at least 11 months later | Recruiting |
12 more on the Trials at Risk page. See which trials →
Phase 2 and Phase 3 trials with a primary completion date in the next 180 days, as ClinicalTrials.gov estimates it today. Active trials only.
| Trial | Scheduled | Phase |
|---|---|---|
| A Study to Test Whether BI 771716 Helps People With an Advanced Form of… NCT06722157 | Oct 28, 2026 · Estimated | Phase 2 |
7 more on the Completions page. See the calendar →
Monitor the Boehringer Ingelheim pipeline daily
Get a daily digest when Boehringer Ingelheim registers new trials or updates existing protocols. Free plan, no credit card required.
Start monitoring free| Condition / indication | Active trials |
|---|---|
| Healthy | 15 |
| Obesity | 10 |
| Interstitial Lung Diseases | 4 |
| Neuroendocrine Neoplasms | 4 |
| Small Cell Lung Carcinoma (SCLC) | 4 |
| Solid Tumours | 4 |
| Heart Failure | 3 |
| Idiopathic Pulmonary Fibrosis | 3 |
Boehringer Ingelheim's SOS1 inhibitor (BI 1701963) in combination with KRAS G12C inhibitors is a major competitive program for anyone active in KRAS-altered NSCLC or CRC. Their Jardiance expansions into HFpEF and CKD are closely watched by companies developing competing SGLT2 or HF therapeutics.
DataLookout monitors ClinicalTrials.gov daily and surfaces changes to Boehringer Ingelheim's registered studies: new trial registrations, status transitions (for example "Not yet recruiting" to "Recruiting"), site additions, and protocol amendments. This is the intelligence layer that bridges the gap between quarterly investor calls and day-to-day pipeline developments.
- Sponsor normalization: Boehringer Ingelheim may register trials under multiple legal entity names. DataLookout normalizes all related entities to a single canonical sponsor for complete pipeline coverage.
- Daily updates: ClinicalTrials.gov is queried each morning. New registrations and updates appear in that day's digest.
- Field-level change detection: Status changes, enrollment updates, and site additions are detected and surfaced, not just new registrations.
- Phase filtering: Focus on Phase 3 pivotal trials, Phase 2 proof-of-concept studies, or all phases for comprehensive coverage.
- Indication filtering: Combine sponsor monitoring with indication keywords to focus on the therapeutic areas relevant to your business.
Automate your Boehringer Ingelheim pipeline intelligence
Used by pharma BD, strategy, and competitive intelligence professionals. Setup takes under 5 minutes.
Get started free| Trial | Status | Latest tracked change | Seen |
|---|---|---|---|
| Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With… NCT04886804 | Active, Not Recruiting | Primary endpoint(s) modified | 2026-10-06 |
| A Study to Test Whether Nerandomilast Helps People With Lung Fibrosis Related… NCT06806592 | Active, Not Recruiting | Enrollment closed, study ongoing | 2026-10-03 |
| The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With… NCT06872892 | Recruiting | Trial sites expanded: 471 → 478 locations | 2026-10-02 |
| FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With… NCT07540988 | Recruiting | Start date changed from estimate of Sep 14, 2026 to Sep 17, 2026 | 2026-10-02 |
| A Study to Test Whether Vicadrostat (BI 690517) in Combination With… NCT06935370 | Recruiting | Trial sites reduced: 588 → 585 locations | 2026-10-02 |
Each trial page shows every change DataLookout has recorded for that trial.